March 11, 2009
Biotech, cancer, Inflammation Luke Timmerman wrote: Some members of the band that pumped out a one-hit wonder at Icos are getting back together to see if they can produce at least one more hit at Seattle-based Calistoga Pharmaceuticals. Calistoga has been building up its management team over the pas...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 10:00 AM
| 2 Citations
March 09, 2009
Roundup, deals, Life Sciences Bruce V. Bigelow wrote: It’s hard for any company to raise capital in this recession, but several San Diego life sciences startups disclosed last week they had done just that. A few bright spots also appeared during a local seminar on mergers and acquisitionsR...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Bruce V. Bigelow
at 4:30 AM
March 06, 2009
Biotech, cancer, Drugs Luke Timmerman wrote: Nowhere but America makes it possible for a company to pursue its dreams for 28 years without making a profit. Even in the most optimistic times, it’s hard to explain. So how can it possibly be, in the depths of recession, that things are looking up...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 6:00 AM
| 2 Citations
March 05, 2009
cleantech, energy, wind Luke Timmerman wrote: British Columbia is bigger in land area than Washington, Oregon, and California combined, but has about one-tenth the total population. Yet pound-for-pound, our neighbor to the north appears to have its share of entrepreneurs thinking hard about energy a...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 5:00 AM
| 5 Citations
March 03, 2009
cleantech, energy, environment Luke Timmerman wrote: The venture capitalist John Doerr of Kleiner Perkins Caufield & Byers said three years ago that “greentech could be the largest economic opportunity of the 21st century.” Since then, voters in the U.S. have elected a President and ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 9:13 AM
| 6 Citations
March 02, 2009
Biotech, FDA, Life Sciences Luke Timmerman wrote: Genzyme got some bad news today from the FDA. The Cambridge, MA-based biotech company said that U.S. regulators determined its drug for Pompe disease made in large-scale vats isn’t ready to be approved for the market. Plus, the FDA sent the com...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 6:25 PM
| 2 Citations
February 26, 2009
Web, deals, Life Sciences Ryan McBride wrote: The story of FetchDog begins with a small group of pet owners who saw a need for an online hub for people like them to buy merchandise, read about trends, and socialize. And the founders of the Portland, ME-based firm, besides their affinity for pets, ar...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Ryan McBride
at 6:00 AM
| 1 Citations
Biotech, cancer, Drugs Luke Timmerman wrote: Off the coast of the Bahamas, in sea grass more than a half-mile deep, San Diego-based Nereus Pharmaceuticals found a fungus that may be the key ingredient for an innovative new cancer drug. This will be a key year for gathering evidence that will either ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 5:00 AM
| 1 Citations
February 24, 2009
Biotech, Lupus, Diagnostics Luke Timmerman wrote: Cypress Bioscience (NASDAQ: CYPB), the San Diego-based developer of a drug for fibromyalgia, said today it has acquired technology from Cellatope to diagnose and monitor hard-to-detect autoimmune diseases like lupus. Cypress and its partner, New York...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 10:07 AM
| 1 Citations
February 23, 2009
Biotech, Patents, vaccines Luke Timmerman wrote: One of the world’s best-selling vaccines, Merck’s Gardasil, is quietly producing some serious money for an unexpected benefactor—the University of Washington. Thanks to some hard-fought patent litigation from the 1990s that ended up ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 3:00 AM
| 3 Citations
